Publication | Closed Access
Phase I Trial of 72-Hour Continuous Infusion UCN-01 in Patients With Refractory Neoplasms
294
Citations
33
References
2001
Year
UCN-01 can be administered safely as an initial 72-hour CIV with subsequent monthly doses administered as 36-hour infusions.
| Year | Citations | |
|---|---|---|
Page 1
Page 1